logo
Plus   Neg
Share
Email
Comment

AstraZeneca Plans To Conduct New Study Of BRILINTA In PAD Patients

AstraZeneca Plc (AZN,AZN.L) unveiled plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease, or PAD, a condition affecting approximately 27 million people in Europe and North America. PAD patients are at high risk of myocardial infarction, strokes, and other health complications.

EUCLID is designed to evaluate cardiovascular event rate and safety in PAD patients. BRILINTA (Ticagrelor) is currently not approved for the treatment of patients with PAD.

EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing the primary endpoint - a composite of cardiovascular death, myocardial infarction or ischemic stroke - in patients with PAD.

In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomized to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalized, the EUCLID steering committee will begin the process of recruiting study investigators, clinical centers, and eventually patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of BHP Billiton plc were losing around 4 percent in the morning trading in London after the Anglo-Australian mining giant reported Tuesday sharply lower profit in its first half on US tax charge, despite higher revenues. Further, the company announced higher dividend, but trimmed its forecast for Group copper equivalent volume growth for fiscal 2018. Asia-focused lender HSBC Holdings Plc reported late Monday a significant growth in fiscal 2017 profit, reflecting higher revenues and the absence of loss related to Brazil operations. The company noted that all of its global businesses grew adjusted profits and three main global businesses generated improved adjusted revenue. Further, the company maintained its dividend. Tech giants Amazon.com, YouTube and Twitter as well as Verizon Communications are exploring bids for digital streaming rights to the National Football League or NFL's Thursday Night Football package, according to media reports. The NFL is likely to strike a multi-year deal for the digital streaming rights. However, the television audience for the NFL has declined for two consecutive years.
comments powered by Disqus
Follow RTT